Here are the 10-Q quarterly reports from Nu-Med Plus Inc (NUMD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NUMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NUMD filings page.
Nu-Med Plus, Inc. reports June 30, 2026 quarterly results showing no revenue, total assets of $12,909 (including cash of $5,409) and liabilities of $280,395, resulting in a stockholders’ deficit of $267,486. The company recorded net income of $19,670 for the quarter and $3,792 for the six months, driven by $45,000 of other income from Avid Gold in exchange for transaction exclusivity.
Management states that current funds only support operations through August 31, 2026 and discloses planned expenditures of approximately $1,200,000 over the next 12 months, raising substantial doubt about the ability to continue as a going concern. Nu-Med Plus completed a share exchange to acquire 100% of Avid Gold via 4,500,000 shares of Series A Preferred Stock and agreed to acquire six Canadian gold properties for 500,000 additional Series A Preferred shares plus assumed liabilities, significantly pivoting toward gold exploration.
The company also highlights substantial related-party notes totaling $122,500, a $100,000 convertible note to be repaid by October 8, 2026, potential issuance of “True-Up” shares to the property vendor, and super-voting and preferred share structures that may lead to significant dilution and concentrated voting control. Disclosure controls and procedures are assessed as not effective.
Nu-Med Plus, Inc. reports unaudited first‑quarter 2026 results with no revenue and a net loss of $15,878, slightly improved from the prior year’s loss. Operating expenses were modest at $13,151, reflecting limited activity while product development remains suspended pending new capital.
As of March 31, 2026, the company had cash of only $4,284, total assets of $7,184, current liabilities of $294,340 and a stockholders’ deficit of $287,156, underscoring a weak balance sheet. Management discloses a working capital deficiency of $286,156 and states that these conditions raise substantial doubt about its ability to continue as a going concern.
Nu-Med Plus is an early‑stage medical device company focused on nitric oxide delivery technologies and currently has no approved products or revenue. It estimates planned expenditures of about $1,200,000 over the next twelve months, including $300,000 for overhead and $900,000 for product development, and expects to rely on equity sales and shareholder loans to fund operations.
Nu‑Med Plus (NUMD) filed its Q3 2025 10‑Q, reporting no revenue and a net loss of $11,966 for the quarter and $43,564 for the nine months ended September 30, 2025. Operating expenses declined year over year, reflecting lower professional fees.
Liquidity remains tight: cash was $1,948 and total assets $5,048 against current liabilities of $263,708, resulting in a working capital deficiency of $258,660. Management disclosed planned expenditures of approximately $1,200,000 over the next twelve months and stated the company is funded through November 30, 2025, raising substantial doubt about continuing as a going concern.
Product development is suspended until capital infusion. Financing relied on related parties, including a $100,000 note to YSA and August 15, 2025 notes of $12,500 and $87,500 at 5% payable on demand. Disclosure controls and procedures were deemed not effective. Common shares outstanding were 83,548,469 as of November 14, 2025.